LeMaitre Vascular (NASDAQ:LMAT) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $98.26 and traded as high as $100.85. LeMaitre Vascular shares last traded at $99.79, with a volume of 224,599 shares traded.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Barrington Research restated an “outperform” rating and set a $120.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Wells Fargo & Company upped their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Finally, Citizens Jmp increased their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Trading Down 1.4%

The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The company has a 50-day simple moving average of $97.13 and a 200 day simple moving average of $98.40. The firm has a market cap of $2.32 billion, a PE ratio of 37.42, a price-to-earnings-growth ratio of 2.77 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter last year, the company earned $0.48 EPS. The business’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were issued a $0.25 dividend. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s payout ratio is presently 36.90%.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at $155,428,765.11. The trade was a 1.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares of the company’s stock, valued at $401,143. The trade was a 43.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 54,453 shares of company stock worth $5,906,174. Company insiders own 7.40% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently bought and sold shares of LMAT. Sound Income Strategies LLC raised its stake in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 183 shares during the period. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular in the 1st quarter valued at $32,000. Geneos Wealth Management Inc. increased its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the second quarter worth $47,000. Finally, GAMMA Investing LLC raised its position in LeMaitre Vascular by 32.7% during the fourth quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 179 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.